The Law Offices of Frank R. Cruz announces that a class action lawsuit has been filed on behalf of shareholders who purchased or otherwise acquired Anavex Life Sciences Corp. (“Anavex” or the “Company”) (NASDAQ: AVXL) common stock between November 26, 2025 and August 28, 2026, inclusive (the “Class Period”). Anavex Life Sciences Corp. investors have until November 30, 2026 to file a lead plaintiff motion.

IF YOU SUFFERED A LOSS ON YOUR ANAVEX LIFE SCIENCES CORP. (AVXL) INVESTMENTS, CLICK HERE TO SUBMIT A CLAIM TO POTENTIALLY RECOVER YOUR LOSSES IN THE ONGOING SECURITIES FRAUD LAWSUIT.

You can also contact the Law Offices of Frank R. Cruz to discuss your legal rights by email at info@frankcruzlaw.com, by telephone at (310) 914-5007, or visit our website at www.frankcruzlaw.com.

What Happened?

On May 11, 2026, the Company filed with the SEC a notification of late filing which disclosed it had “terminated the employment of Dr. Christopher Missling as the Chief Executive Officer of the Company on April 30, 2026 for, among other things, conduct that the Special Committee believed was inconsistent with Company Policy.”

On this news, Anavex stock fell $0.18 per share, or 5.55%, to close at $3.06 on May 12, 2026, thereby injuring investors.

On August 28, 2026, Anavex filed an Amended 2025 Annual Report with the SEC. The report stated, in part, that as a result of a review by the Special Committee, management, in consultation with the Audit Committee of the Board, “concluded that there was a material weakness in internal control over financial reporting that existed at September 30, 2025” and that “the Company’s disclosure controls and procedures were not effective.”

On this news, Anavex stock fell $0.19 per share, or 6.35%, to close at $2.80 on August 31, 2026, thereby injuring investors further.

What Is The Lawsuit About?

The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) Anavex lacked adequate internal controls; (2) Anavex understated its potential regulatory challenges as a result of misconduct by former CEO Christopher Missling; and (3) as a result, Defendants’ statements about Anavex’s business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.

Contact Us To Participate or Learn More:

If you purchased Anavex common stock, wish to learn more about this action, or have any questions concerning this announcement or your rights or interests with respect to these matters, please click HERE or contact us at:

Law Offices of Frank R. Cruz
2121 Avenue of the Stars, Suite 800
Century City, CA 90067
Telephone: 310-914-5007
Email: info@frankcruzlaw.com
Visit our website at: www.frankcruzlaw.com

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

View source version on businesswire.com: https://www.businesswire.com/news/home/20261001710938/en/

Law Offices of Frank R. Cruz Encourages Anavex Life Sciences Corp. (AVXL) Shareholders To Inquire About Securities Fraud Class Action